ArticleOncotarget2017

A retrospective comparative study of progression-free survival and overall survival between metachronous and synchronous metastatic renal cell carcinoma in intermediate- or poor-risk patients treated with VEGF-targeted therapy.

Sung Han Kim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.